279 related articles for article (PubMed ID: 16842143)
21. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
Bruckert E; Ferrières J
Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
[TBL] [Abstract][Full Text] [Related]
22. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
[TBL] [Abstract][Full Text] [Related]
23. Prevention of cardiovascular ischemic events: high-risk and secondary prevention.
Genest J; Pedersen TR
Circulation; 2003 Apr; 107(15):2059-65. PubMed ID: 12707251
[No Abstract] [Full Text] [Related]
24. [Pharmacotherapy after cardiac infarction].
Darius H; Meyer J
Internist (Berl); 2001 May; 42(5):699-712. PubMed ID: 11400577
[No Abstract] [Full Text] [Related]
25. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Hippisley-Cox J; Coupland C
BMJ; 2005 May; 330(7499):1059-63. PubMed ID: 15879390
[TBL] [Abstract][Full Text] [Related]
26. [Secondary prevention of acute coronary syndromes: are we following correctly the guidelines?].
Casella G; Greco C; Maggioni AP; Di Pasquale G
G Ital Cardiol (Rome); 2006 Mar; 7(3):176-85. PubMed ID: 16572983
[TBL] [Abstract][Full Text] [Related]
27. Quality of medical management in coronary artery disease.
Al Shammeri O; Stafford RS; Alzenaidi A; Al-Hutaly B; Abdulmonem A
Ann Saudi Med; 2014; 34(6):488-93. PubMed ID: 25971821
[TBL] [Abstract][Full Text] [Related]
28. Benefits of aggressive drug therapy.
Oken K; Fletcher G
J Cardiovasc Nurs; 2003; 18(2):79-84. PubMed ID: 12680565
[TBL] [Abstract][Full Text] [Related]
29. Statins and aspirin: do they really work in women?
Desai H; Hollingsworth PW; Chugh AR
Am J Cardiovasc Drugs; 2015 Jun; 15(3):151-62. PubMed ID: 25812803
[TBL] [Abstract][Full Text] [Related]
30. Secondary prevention of coronary heart disease in the elderly.
Dornbrook-Lavender KA; Roth MT; Pieper JA
Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
[TBL] [Abstract][Full Text] [Related]
31. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
[TBL] [Abstract][Full Text] [Related]
32. Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease.
Ladapo JA; Hoffmann U; Lee KL; Coles A; Huang M; Mark DB; Dolor RJ; Pelberg RA; Budoff M; Sigurdsson G; Severance HW; Douglas PS
J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27733347
[TBL] [Abstract][Full Text] [Related]
33. Rationale and design for a cluster randomized quality-improvement trial to increase the uptake of evidence-based therapies for patients at high cardiovascular risk: The BRIDGE-Cardiovascular Prevention trial.
Machline-Carrion MJ; Soares RM; Damiani LP; Campos VB; Sampaio B; Yamashita J; Fonseca FH; Izar MC; Amodeo C; Pontes-Neto OM; de Melo Barros PG; Lopes RD; Brandão da Silva N; Guimarães HP; Piegas L; Stein AT; Berwanger O
Am Heart J; 2019 Jan; 207():40-48. PubMed ID: 30415082
[TBL] [Abstract][Full Text] [Related]
34. Secondary prevention of coronary artery disease in contemporary clinical practice.
Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
[TBL] [Abstract][Full Text] [Related]
35. Office management of peripheral arterial disease.
Aronow WS
Am J Med; 2010 Sep; 123(9):790-2. PubMed ID: 20800143
[TBL] [Abstract][Full Text] [Related]
36. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
Voors AA; van Veldhuisen DJ; van Gilst WH
Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
[No Abstract] [Full Text] [Related]
37. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
[TBL] [Abstract][Full Text] [Related]
38. Secondary prevention after acute myocardial infarction and coronary revascularisation: focus on Angiotensin converting enzyme inhibitors.
Kaski JC; Fernandez-Berges D
Cardiovasc Drugs Ther; 2008 Jun; 22(3):185-91. PubMed ID: 18317916
[TBL] [Abstract][Full Text] [Related]
39. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.
Khatib R; McKee M; Shannon H; Chow C; Rangarajan S; Teo K; Wei L; Mony P; Mohan V; Gupta R; Kumar R; Vijayakumar K; Lear SA; Diaz R; Avezum A; Lopez-Jaramillo P; Lanas F; Yusoff K; Ismail N; Kazmi K; Rahman O; Rosengren A; Monsef N; Kelishadi R; Kruger A; Puoane T; Szuba A; Chifamba J; Temizhan A; Dagenais G; Gafni A; Yusuf S;
Lancet; 2016 Jan; 387(10013):61-9. PubMed ID: 26498706
[TBL] [Abstract][Full Text] [Related]
40. Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Lloyd GM; Newton JD; Norwood MG; Franks SC; Bown MJ; Sayers RD
J Vasc Surg; 2004 Oct; 40(4):691-7. PubMed ID: 15472596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
